vidarabine has been researched along with Lymphoma in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (11.76) | 18.7374 |
| 1990's | 15 (17.65) | 18.2507 |
| 2000's | 37 (43.53) | 29.6817 |
| 2010's | 22 (25.88) | 24.3611 |
| 2020's | 1 (1.18) | 2.80 |
| Authors | Studies |
|---|---|
| Derlon, JM; Gourand, F; Guillouet, S; Kalaeva, D; Khokholova, E; Kobyakov, G; Maryashev, S; Pitskhelauri, D; Postnov, A; Potapov, A; Pronin, I; Pyzhik, E; Rizhova, M; Toutain, J; Usachev, D; Valable, S; Vikhrova, N | 1 |
| Abedi-Valugerdi, M; Benkessou, F; Hassan, M; Zhao, Y; Zheng, W | 1 |
| Barré, L; Fillesoye, F; Gourand, F; Guillouet, S; Hovhannisyan, N; Ibazizene, M; Plancoulaine, B; Toutain, J; Valable, S | 1 |
| Haeusler, GM; Lingaratnam, S; Seymour, JF; Slavin, MA; Tam, CS; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Barré, L; Delamare, J; Deloye, JB; Gourand, F; Guillouet, S; Leporrier, M; Patin, D; Tirel, O | 1 |
| Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A | 1 |
| Dijkstra, FS; Janssen, JJ; Ossenkoppele, GJ; Visser, OJ; Witte, BI; Wondergem, MJ; Zweegman, S | 1 |
| Almazi, JG; Best, OG; Christopherson, RI; Kohnke, PL; Mactier, S; Mulligan, SP | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W | 1 |
| Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L | 1 |
| Brenner, MK; Dotti, G; Heslop, HE; Huye, L; Narala, N; Ninomiya, S; Ramos, CA; Rooney, CM; Savoldo, B; Yagyu, S | 1 |
| Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R | 1 |
| Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Seol, M | 1 |
| Antin, JH; Armand, P; Caballero, D; Cabrero, M; Esquirol, A; Kekre, N; Lopez-Corral, L; Marquez-Malaver, FJ; Martino, R; Pérez-Simon, JA; Piñana, J; Soiffer, RJ; Solano, C; Terol, MJ | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Christopherson, RI; Crossett, B; Gez, S; Henrich, S; Mulligan, SP | 1 |
| Aksoy, S; Dizdar, O; Harputluoğlu, H; Hayran, M | 1 |
| Brown, JR; Dal Cin, P; Feng, Y; Fisher, DC; Fisher, RI; Freedman, AS; Friedberg, JW; Joyce, R; Liesveld, J; Marquis, D; Neuberg, D; Phillips, K; Scofield, S; Takvorian, RW | 1 |
| Chen, X; Tian, LP; Wang, JS; Wang, Z; Wu, L | 1 |
| Anasetti, C; Ayala, E; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Perkins, J; Pidala, J; Roman-Diaz, J; Tate, C; Tomblyn, M | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Ayari, S; Blin, N; Brissot, E; Cahu, X; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Harousseau, JL; Le Gouill, S; Mahe, B; Malard, F; Miplied, N; Mohty, M; Moreau, P | 1 |
| Iwasaki, H; Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Neumann, T; Wilfert, H | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Dunleavy, K; Fowler, DH; Fry, TJ; Gress, RE; Hakim, F; Hughes, TE; Odom, J; Pavletic, SZ; Salit, RB; Steinberg, SM; Wilson, WH | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Ayari, S; Blin, N; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lestang, E; Mahe, B; Mohty, M; Moreau, P; Planche, L; Roland, V; Tessoulin, B | 1 |
| Balzarotti, M; Bertuzzi, A; Castagna, L; Farè, M; Grimoldi, MG; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I | 1 |
| Bolaños-Meade, J; Khanwani, SL; Sarkodee-Adoo, C | 1 |
| Azuma, T; Fujita, S; Ishimura, M; Takada, K; Yamauchi, H; Yasukawa, M | 1 |
| Giralt, S; Goldman, JM; Hale, G; Mackinnon, S; Slavin, S; Waldmann, H | 1 |
| Fruchtman, S; Grosskreutz, C; Isola, L; Ross, V; Scigliano, E | 1 |
| Akagi, T; Hayashi, K; Jin, ZS; Joko, H; Koirala, TR; Kondo, E; Munemasa, M; Oda, W; Ohara, N; Oka, T; Onoda, S; Takahashi, K; Tanaka, T; Yamada, M; Yoshino, T | 1 |
| Fil'chenkov, AA; Nesina, IP; Smirnova, IA; Zavelevich, MP | 1 |
| Champlin, RE; Khouri, IF | 1 |
| Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A | 1 |
| Nicolle, A; Proctor, SJ; Summerfield, GP | 1 |
| Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A | 1 |
| Assmann, M; Bartsch, R; Eschenburg, H; Franke, A; Herold, M; Jentsch-Ullrich, K; Kahl, C; Knauf, W; Koenigsmann, M; Lakner, V; Mohren, M; Müller, G; Pasold, R | 1 |
| Grigg, AP; Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Delarue, R; François, S; Hermine, O; Ifrah, N; Lefrère, F; Lévy, V; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
| Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F | 1 |
| Jaeger, U; Johnson, SA; Leblond, V; Levy, V; Oscier, DG; Owen, RG; Seymour, JF | 1 |
| Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M | 1 |
| Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A | 1 |
| Alinari, L; Baccarani, M; Fina, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Bowen, DA; Call, TG; Habermann, TM; Hoyer, JD; Jelinek, DF; Kay, NE; Maddocks-Christianson, K; Reinalda, M; Schwager, S; Shanafelt, TD; Slager, SL; Zent, CS | 1 |
| Cattaneo, R; Frenzke, ME; Johnston, PB; Lampe, J; Parker, WB; Sorscher, EJ; Springfeld, C; Ungerechts, G | 1 |
| Byrd, J; Cheney, C; Chu, P; Hariharan, K; Molina, A; Pathan, NI | 1 |
| Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A | 1 |
| Bakay, B; Bleeker, LC; Kung, FH; Matsumoto, SS; Nyhan, WL; Yu, AL | 1 |
| Alford, CA; Betts, R; Dolin, R; Linnemann, C; Soong, SJ; Whitley, RJ | 1 |
| Busk, CM; Earl, HM; Lister, TA; Wrigley, PF | 1 |
| Hiddemann, W; Pott-Hoeck, C | 1 |
| Piro, LD; Saven, A | 2 |
| Saven, A | 1 |
| Cabanillas, F; Gandhi, V; Gregoire, V; Keating, MJ; McLaughlin, P; O'Brien, S; Plunkett, W; Robertson, LE; Yang, L | 1 |
| Cabanillas, F; Hagemeister, FB; Keating, M; McLaughlin, P; Pate, O; Romaguera, JE; Sarris, AH; Swan, F; Younes, A | 1 |
| Wiley, JS | 1 |
| Bolam, S; Orchard, J; Oscier, D | 1 |
| Nagler, A; Slavin, S | 1 |
| Cheson, BD | 2 |
| Bardy, P; Byron, K; Grigg, A; Seymour, JF; Szer, J | 1 |
| Arnaud, MC; Otto, J; Pivot, X; Schneider, M; Tchiknavorian, X; Thyss, A | 1 |
| Bernard, N; Beylot, J; Delevaux, I; Lacoste, D; Morlat, P; Nouts, C | 1 |
| Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G | 1 |
| Catovsky, D; Dearden, CE; Matutes, E | 1 |
| Dai, Y; Decker, R; Dent, P; Grant, S; Harvey, S; Kramer, L; Schaefer, G; Tang, L | 1 |
| Ariola, C; Cordone, I; Fazi, F; Fenu, S; Mandelli, F; Montefusco, E; Nanni, M; Petti, MC; Spadea, A; Spiriti, MA | 1 |
| Bertz, H; Finke, J; Illerhaus, G; Veelken, H | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Itälä, M; Remes, K | 1 |
| Albertini, RJ; Aronson, MD; Gump, DW; Phillips, CA; Phillips, CF | 1 |
| Maidhof, A; Müller, WE; Shannon, WM; Zahn, RK | 1 |
| Rand, KH | 1 |
| Beyer, R; Kahn, RK; Lachmann, M; Maidhof, A; Müller, WE; Rohde, HJ; Taschner, H | 1 |
| Robak, T | 1 |
| Hirose, M; Inaba, S; Kuroki, Y; Shimoyama, M | 1 |
| Dandliker, PS; Meyers, JD; Shepp, DH | 1 |
| Asano, Y; Fujimoto, K; Harada, M; Moriyama, K; Niho, Y; Okamura, T; Shibuya, T | 1 |
13 review(s) available for vidarabine and Lymphoma
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma; Neutropenia; Opportunistic Infections; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2009 |
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2002 |
Fludarabine in the management of malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Incidence; Lymphoma; Lymphoma, Non-Hodgkin; Mycoses; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma; Pentostatin; Vidarabine | 1993 |
Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia; Lymphoma; Molecular Structure; Pentostatin; Purine Nucleosides; Vidarabine | 1993 |
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Structure; Multicenter Studies as Topic; Radiation-Sensitizing Agents; Remission Induction; Tumor Cells, Cultured; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
2-Chlorodeoxyadenosine treatment of lymphoma.
Topics: Adenosine Deaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Pentostatin; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunotherapy, Adoptive; Interleukin-2; Lymphoma; Neoplasm Recurrence, Local; Neoplasm, Residual; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1998 |
Cellular and clinical pharmacology of fludarabine.
Topics: Antineoplastic Agents; Biological Availability; Deoxycytidine Kinase; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation, Preclinical; Humans; Leukemia; Lymphoma; Phosphorylation; Vidarabine; Vidarabine Phosphate | 2002 |
[Nucleoside analogues--new drugs for the treatment of lymphatic cancers].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphoid; Lymphoma; Nucleosides; Pentostatin; Vidarabine | 2001 |
New antimetabolites in the treatment of human malignancies.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Pentostatin; Purines; Vidarabine | 1992 |
[New analogs of deoxyadenosine for treatment of lymphoid malignancies].
Topics: Antineoplastic Agents; Cladribine; Deoxyadenosines; Formycins; Humans; Leukemia; Lymphoma; Vidarabine | 1992 |
20 trial(s) available for vidarabine and Lymphoma
| Article | Year |
|---|---|
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Sirolimus; Stem Cell Transplantation; Survival Rate; Tacrolimus; Vidarabine | 2015 |
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2015 |
A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2015 |
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Rituximab; Survival Rate; Vidarabine | 2009 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Bone Marrow Diseases; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Radiotherapy Dosage; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Nonmyeloablative stem cell transplantation for lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma; Middle Aged; Recurrence; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2004 |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Germany; Hematology; Humans; Lymphoma; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Societies, Medical; Time Factors; Vidarabine | 2004 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine | 2005 |
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Splenic Neoplasms; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Time Factors; Treatment Outcome; Vidarabine | 2005 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine | 2008 |
Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients.
Topics: Adolescent; Adult; Double-Blind Method; Drug Evaluation; Female; Herpes Zoster; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Male; Middle Aged; Neuralgia; Time Factors; Vidarabine | 1982 |
Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone; Opportunistic Infections; Recurrence; Treatment Outcome; Vidarabine | 1996 |
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Topics: Adult; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Recurrence; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine.
Topics: Acyclovir; Adolescent; Adult; Child; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immune Tolerance; Leukemia; Lymphoma; Male; Prospective Studies; Random Allocation; Vidarabine | 1986 |
52 other study(ies) available for vidarabine and Lymphoma
| Article | Year |
|---|---|
First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine.
Topics: Adrenal Cortex Hormones; Brain Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Glioblastoma; Humans; Lymphoma; Methionine; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Vidarabine | 2022 |
Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Growth Processes; Cell Line, Tumor; Female; Fluorouracil; Immune Tolerance; Lymphoma; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Vidarabine | 2017 |
[
Topics: Animals; Central Nervous System Neoplasms; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Heterografts; Histocytochemistry; Humans; Image Processing, Computer-Assisted; Lymphoma; Magnetic Resonance Imaging; Neoplasm Transplantation; Positron-Emission Tomography; Radiopharmaceuticals; Rats, Nude; Sensitivity and Specificity; Vidarabine | 2018 |
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Rituximab; Treatment Outcome; Vidarabine | 2013 |
Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.
Topics: Automation; Chromatography, High Pressure Liquid; Fluorine Radioisotopes; Humans; Lymphoma; Positron-Emission Tomography; Quality Control; Vidarabine | 2014 |
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Lymphoma; Tumor Suppressor Proteins; Unfolded Protein Response; Vidarabine | 2014 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult | 2015 |
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Topics: Animals; Antigens, CD19; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclophosphamide; Disease Models, Animal; Down-Regulation; Flow Cytometry; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphoma; Mice; Mice, SCID; Real-Time Polymerase Chain Reaction; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; T-Lymphocytes; Vidarabine; Xenograft Model Antitumor Assays | 2015 |
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
Topics: Animals; Antibodies; Antigens, CD; Apoptosis; Cattle; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Tumor Suppressor Protein p53; Vidarabine | 2008 |
[Clinical analysis of 14 patients with lymphoma associated hemophagocytic syndrome].
Topics: Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Prognosis; Retrospective Studies; Treatment Outcome; Vidarabine | 2009 |
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Retrospective Studies; Rituximab; Transplantation Conditioning; Vidarabine | 2011 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia; Lymphoma; Salvage Therapy; Vidarabine | 2011 |
Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukocyte Count; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Myelodysplastic Syndromes; Platelet Count; Statistics as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-15; Interleukin-7; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Prednisone; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Innate; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Neoplasms, Second Primary; Time Factors; Vidarabine | 2002 |
Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphocytes; Lymphoma; Remission Induction; Splenic Neoplasms; Vidarabine | 2002 |
Therapeutic trials for a rabbit model of EBV-associated Hemophagocytic Syndrome (HPS): effects of vidarabine or CHOP, and development of Herpesvirus papio (HVP)-negative lymphomas surrounded by HVP-infected lymphoproliferative disease.
Topics: Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell Line; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Genome, Viral; Herpes Simplex; Histiocytosis, Non-Langerhans-Cell; Humans; Immunoglobulin G; Lymphoma; Lymphoproliferative Disorders; Papio; Phenotype; Prednisone; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Simplexvirus; Survival Analysis; Vidarabine; Vincristine | 2003 |
Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatids; Chromosome Aberrations; Chromosomes; Culture Media; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Humans; Karyotyping; Lymphoma; Mutagens; Vidarabine | 2003 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Vincristine | 2003 |
High dose chlorambucil in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine | 2004 |
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Neoplasm Staging; Opportunistic Infections; Risk Factors; Vidarabine | 2004 |
Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
Topics: Adult; Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphocytes; Lymphoma; Middle Aged; Splenectomy; Splenic Neoplasms; Vidarabine | 2004 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine | 2005 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dexamethasone; Female; Humans; Immunosuppression Therapy; Infections; Interferons; Lymphoma; Male; Middle Aged; Mitoxantrone; Neutropenia; Vidarabine | 2005 |
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Purine Nucleotides; Risk Factors; Vidarabine | 2007 |
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; Chlorocebus aethiops; Drug Therapy; Humans; Lymphoma; Measles virus; Membrane Cofactor Protein; Mice; Mice, Transgenic; Prodrugs; Purine-Nucleoside Phosphorylase; Vero Cells; Vidarabine | 2007 |
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Mice; Mitochondria; Mitochondrial Proteins; Protease Inhibitors; Receptors, IgE; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Vidarabine; Xenograft Model Antitumor Assays | 2008 |
Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Topics: Adenosine Deaminase; Adolescent; Deoxyadenine Nucleotides; Deoxyadenosines; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Lymphoma; Male; Nucleotidases; Pentostatin; Thymidine; Vidarabine | 1982 |
Triple drug therapy of Herpes zoster infection occurring in patients with reticulo-endothelial neoplasia--a preliminary study.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Herpes Zoster; Hodgkin Disease; Humans; Idoxuridine; Immunoglobulins; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Multiple Myeloma; Neoplasms; Vidarabine | 1980 |
Developments in the treatment of leukaemias and lymphomas.
Topics: Animals; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Vidarabine | 1995 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma; Male; Splenic Neoplasms; Vidarabine | 1997 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Stem Cells; Vidarabine | 1999 |
Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin.
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Humans; Lymphoma; Splenectomy; Splenic Neoplasms; Treatment Outcome; Vidarabine | 1999 |
[The heart in air].
Topics: Aged; Antineoplastic Agents; Cardiac Tamponade; Fatal Outcome; Humans; Lymphoma; Male; Pericardiocentesis; Pneumopericardium; Rupture, Spontaneous; Stomach Ulcer; Tomography, X-Ray Computed; Vidarabine | 2000 |
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2000 |
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine | 2000 |
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Arabinonucleotides; Blotting, Western; Drug Interactions; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Lymphoma; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells; Vidarabine | 2001 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Neoplasms, Multiple Primary; Remission Induction; Vidarabine | 2001 |
Vidarabine therapy for severe herpesvirus infections. An unusual syndrome of chronic varicella and transient immunologic deficiency.
Topics: Adolescent; Adult; Chickenpox; Chronic Disease; Cytomegalovirus Infections; Encephalitis; Female; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Pneumonia, Viral; Purine Nucleosides; Skin Diseases, Infectious; Syndrome; Vidarabine | 1976 |
Effect of 9-beta-D-arabinofuranosyladenine on DNA synthesis in vivo.
Topics: Adenosine Deaminase; Adenosine Triphosphate; Arabinose; Binding, Competitive; Cell Division; Cells, Cultured; Deoxyadenosines; DNA-Directed RNA Polymerases; DNA, Neoplasm; Lymphoma; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Vidarabine | 1977 |
Herpes zoster. Of antibodies and antivirals.
Topics: Antibodies, Viral; Herpes Zoster; Humans; Lymphoma; Vidarabine | 1979 |
Mode of action of 9-beta-D-arabinofuranosyladenine on the synthesis of DNA, RNA, and protein in vivo and in vitro.
Topics: Animals; Cell Division; Cell Line; Cell-Free System; Depression, Chemical; DNA; DNA Nucleotidyltransferases; DNA Replication; DNA-Directed RNA Polymerases; Female; Lymphoma; Lysine; Molecular Weight; Polynucleotide Adenylyltransferase; Polyribosomes; Protein Biosynthesis; Purine Nucleosides; Quail; RNA; Thymidine; Transcription, Genetic; Uridine; Vidarabine | 1975 |
Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Topics: Adenosine Deaminase; Antineoplastic Agents; Cell Division; Coformycin; Drug Stability; Drug Synergism; Humans; Leukemia; Lymphoma; Pentostatin; Ribonucleosides; Tumor Cells, Cultured; Vidarabine | 1989 |
Successful combination therapy with acyclovir and vidarabine for disseminated varicella zoster virus infection with retinal involvement in a patient with B-cell lymphoma and adult T-cell leukemia.
Topics: Acyclovir; B-Lymphocytes; Drug Therapy, Combination; Female; Fluorescein Angiography; Herpes Zoster; Humans; Leukemia, T-Cell; Lymphoma; Middle Aged; Necrosis; Recurrence; Retinitis; Vidarabine | 1988 |